Use of atypical antipsychotics in people with intellectual disability - Is it atypical?

British Journal of Developmental Disabilities

Volumn 54, Issue 2, 2008, Pages 101-111

  Tin, Nyunt Nyunt ^a   Devapriam, John ^a   Raju, Lammata Bala ^a   Bhaumik, Sabyasachi ^a  

^a Leicester Frith Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; AUTISM; BIPOLAR DISORDER; CLINICAL PRACTICE; COMMUNITY; DEMENTIA; DEMOGRAPHY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HOME; HUMAN; HYPERACTIVITY; INTELLECTUAL IMPAIRMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL INFORMATION; METHODOLOGY; MOOD DISORDER; NATIONAL HEALTH SERVICE; PERSONALITY DISORDER; POPULATION; PRESCRIPTION; PREVALENCE; PSYCHIATRY; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT INDICATION; WEIGHT GAIN;

EID: 47549100701     PISSN: 09697950     EISSN: None     Source Type: Journal    
DOI: 10.1179/096979508799103288     Document Type: Article

References (28)

1. Aman, M. and Singh, N. (1988). Patterns of drug use, methodological consideration, measurements techniques and future trends. Psychopharmacology of Developmental Disabilities, 1-29.
2. Ashcroft, R., Fraser, B., Kerr M. and Ahmed, Z. (2001). Are antipsychotic drugs the right treatment for CB in learning disability?: The place of randomised trial. Journal of Medical Ethics, 27, 338-343.
3. Bhaumik, S. and Branford, D. (editors) (2005). The Frith Prescribing Guidelines for adults with Learning Disability. Leicestershire Partnership NHS Trust, Taylor & Francis Group. London and New York, Chapters 5-9.
4. Bhaumik, S. and Michael D.M. (2004). Pharmacotherapy and Pharmacovigilance in learning disability; Learning Disability Psychiatry, 6, 9-10.
5. Bokszanska, A., Martin, G., Vanstraelen, M., Holt, G., Bouras, N. and Taylor, D. (2003). Risperidone and Olanzapine in adults with intellectual disability: a clinical naturalistic study. International Clinical Psychopharmacology, 18, 285-291.
6. British National Formulary, (2007). Drugs used in psychosis and related disorders, Atypical antipsychotics, 54, 191-195.
7. Branford, D. (1994). A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. Journal of Intellectual Disability Research, 38, 577-586.
8. Branford, D. (1996). A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire, Journal of Intellectual Disability Research, 40, 358-368.
9. Brylewski, J. and Duggan L. (2003). Antipsychotic medication for Challenging Behaviour in People with Intellectual Disability. Cochrane database of systematic reviews (I: 3), 1-26.
10. Clarke, D.J., Kelly, S., Thinn, K. and Corbett, J.A. (1990). Psychotropic drugs and mental retardation. 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. Journal of Mental Deficiency Research, 34, 385-395.
11. Cohen, S.A., Ihrig, K., Lott, R.S. and Kerrick, J.M. (1998). Risperidone for aggression and self-injurious behavior in adults with mental retardation. Journal of Autism and Developmental Disorders, 28, 229-233.
12. Deb, S., Clarke, D. and Unwin, G. (2006). Using medication to manage behaviour problems among adults with a learning disability. QUICK REFERENCE GUIDE University of Birmingham, Birmingham
13. Deb, S. and Unwin, G. (2007). Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature. Current opinion in Psychiatry 20, 461-466.
14. Deb, S., Sohanpal, S.K., Soni, R., Lenotre, L. and Unwin, G. (2007). The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. Journal of Intellectual Disability Research, 51, 766-777.
15. Grey, I.M. and Hastings, R.P. (2005). Evidence-based practices in intellectual disability and behaviour disorders. Current Opinion in Psychiatry, 18, 469-475.
16. Horrigan, J.P. and Barnhill, L.J. (1997). Risperidone and Explosive Aggressive Autism. Journal of Autism and Developmental Disorders, 27, 313-323.
17. Khan, B.U. (1997). Brief report: Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. Journal of Autism and Developmental Disorders, 27, 479-489.
18. Kroese, B.S., Dewhurst, D. and Holmes, G. (2001). Diagnosis and Drugs: Help or hindrance when people with learning disabilities have psychological problems?, British Journal of Learning Disabilities, 29, 26-33.
19. Leicestershire Learning Disability Register, http://www2.le.ac.uk/ departments/health-sciences/extranet/ECC/health-and-disability/projects/LDR/ population, accessed November 2007.
20. McDougle, C.J., Holmes, J.P., Carlson, D.C., Pelton, G.H., Cohen, DJ. and Price, L.H. (1999). A double-blind placebo-controlled study of Risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives General Psychiatry 55, 633-641.
21. McGillivray, J.A. and McCabe, M.P. (2004). Pharmacological management of Challenging Behaviour of individuals with Intellectual Disability. Research in Developmental Disabilities 25, 523-537.
22. McGillivray, J.A. and McCabe, M.P. (2006). Emerging Trends in the use of Drugs to manage Challenging Behaviour of people with Intellectual Disability. Journal of Applied Research in Intellectual Disability 19, 163-172.
23. Reyes, M., Buitelaar, J., Toren, P., Augustyns, I. and Eerdekens, M. (2006). A randomised double-blind, placebo-controlled study of Risperidone maintenance treatment in children and adolescents with disruptive behaviour disorder. American Journal of Psychiatry 163, 402-410.
24. Royal College of Psychiatrists (RCPsych) 2001. Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities/Mental Retardation (DCLD), Gaskell Press, London, p 8-9.
25. Rush, AJ. and Frances, A, (editors) (2000). Expert Consensus Guideline Series: Treatment of psychiatric and behavioural problems in mental retardation. American Journal on Mental Retardation, 105, 159-228.
26. Tyrer, P., Oliver-Africano, P.C., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., Murphy, D., Hare, M., Meade, M., Reece, B., Kramo, K., Bhaumik, S., Harley, D., Regan, A., Thomas, D., Rao, B., North, B., Eliahoo, J., Karatela, S., Soni, A. and Crawford, M. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet, 371, 57-63.
27. Williams, H., Clarke, R., Bouras, N., Martin J. and Holt, G. (2000). Use of the atypical antipsychotics olanzapine and risperidone in adults with intellectual disability. Journal of Intellectual Disability Research, 44, 164-169.
28. Zarcone, J.R., Hellings, J.A., Crandall, K., Reese, R.M., Marquis, J., Fleming, K., Shores, R., Williams, D. and Schroeder, S.R. (2001). Effects of Risperidone on Aberrant Behavior in Persons with Developmental Disabilities: I. A Double-Blind Crossover Study Using Multiple Measures, American Journal on Mental Retardation, 106, 525-538.